Blood Group Typing Market

Blood Group Typing Market by Product (Consumables, Instruments, Services), Test Type (ABO, Antigen, Antibody, HLA), Technique (Assay-based, PCR, Microarray, Massively Parallel Sequencing), End User (Hospital, Blood Banks), Region - Global Forecast to 2028

Report Code: MD 5210 Sep, 2023, by marketsandmarkets.com

The global blood group typing market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.0 billion by 2028, growing at a CAGR of 8.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The increasing frequency of road accidents contributes to the expansion of the market. Road accidents and trauma can lead to physical injuries, hemorrhagic shock, and chronic anemia, which can require major surgeries. The urgent need for blood transfusion in patients requiring immediate surgical intervention may affect the performance of testing, resulting in inadequate and incompatible blood transfusion. Compatibility testing is performed before a blood transfusion to check the compatibility of donor and recipient blood to prevent erroneous blood transfusions.

Attractive Opportunities in the Blood Group Typing Market

Blood Group Typing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Blood Group Typing Market

Blood Group Typing Market Dynamics

DRIVER: The increasing prevalence of chronic diseases and the rising number of surgical procedures necessitate the need for blood donations

With the growth in the prevalence of chronic diseases and surgical procedures for their treatment, the demand for blood has increased. Patients with chronic conditions often require regular blood transfusions to manage their conditions, while surgical procedures, especially major surgeries, necessitate significant amounts of blood for safe and successful outcomes. Consequently, the healthcare system has seen a steady rise in the need for blood, prompting a corresponding increase in blood donations. This is expected to positively impact the market. According to the American National Red Cross (2023), approximately 29,000 units of red blood cells are needed every day in the US in hospitals and emergency treatment facilities to treat patients suffering from chronic diseases and patients undergoing complex surgical procedures. According to the same source, ~16 million units of blood components are transfused in the US in a year.

RESTRAINT: Emergence of blood alternatives

The search for blood substitutes is not new. There already exists factor concentrates to replace fresh-frozen plasma. Although oxygen carriers in the form of perfluorocarbons have not been successful on a large scale, cultured RBCs & platelets can still replace allogeneic platelets and red cells.

Research has shown proof that red cells can be generated from stem cells. In vitro, the generation of RBCs or cultured RBCs (cRBCs) from pluripotent stem cells remains a distinct possibility. If this happens, the concepts of voluntary blood donation, blood testing, and the use of pathogen inactivation by blood centers will all become redundant. There will be minimal need for grouping, cross-matching, and testing.

OPPORTUNITY: Growth opportunities in emerging economies

Emerging economies such as South Korea, Malaysia, Vietnam, Africa, and Middle Eastern countries like Israel, Saudi Arabia, and the UAE offer significant growth opportunities to major market players operating in the market. This can be attributed to the healthcare infrastructural improvements in these countries, the growing patient population, and the rising healthcare expenditure.

Moreover, the disposable income of populations in developing and emerging countries is on the rise. This increase is another key indicator of expanding access to healthcare. According to the OECD, the purchasing power of the growing middle-class population is expected to increase to 59% by 2020 from 23% in 2009. According to the Ministry of Statistics and Programme Implementation (MOSPI), the total Gross National Disposable Income (GNDI) in India increased to USD 20,769.9 million (INR 1,538,430 million) per capita in 2019–2020. With rising disposable incomes and the increasing medical needs of the middle-class population, blood group typing product manufacturers are compelled to devise new strategies to meet this demand. Currently, emerging markets are underpenetrated by major players, which indicates a huge untapped market potential.

Blood Group Typing Ecosystem/Market Map

Blood Group Typing Market Ecosystem

Consumables segment accounted for the largest share of the blood group typing industry in 2022, by product & service.

The blood group typing market is categorized into consumables, instruments, and services & software based on product & service. The consumables segment emerged as the dominant force in the market in 2022. The recurring cost associated with the frequent requirement of reagents & kits is a significant factor contributing to the market's growth. Furthermore, technological advancements in the market continuously drive the development of new and improved reagents.

ABO blood tests & Rh typing segment accounted for the largest share in the blood group typing industry in 2022, by test type.

The global blood group typing market is categorized into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing based on test type. In 2022, the ABO blood tests & Rh typing segment held the largest share in the global market, categorized by test type. ABO blood tests and Rh typing are often conducted in tandem to provide a comprehensive blood typing profile. While ABO typing categorizes blood into four main groups (A, B, AB, and O), Rh typing determines the presence or absence of the Rh factor (Rh-positive or Rh-negative). This dual approach enhances compatibility assessment, covering major antigens influencing transfusion and transplantation outcomes.

Assay-based techniques segment accounted for the largest share in the blood group typing industry in 2022, by technique.

Based on techniques, the blood group typing market has been segmented into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. In 2022, the assay-based techniques segment accounted for the largest share of the global market. While the tube and slide methods have been foundational in blood group typing, the gel column and microplate methods have emerged as the largest and most sophisticated segments in this field. Their automation, increased sensitivity, objectivity in result interpretation, and high-throughput capabilities make them the preferred choice for modern blood banks, hospitals, and clinical laboratory settings.

North America accounted for the largest share of the blood group typing industry in 2022.

The blood group typing market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the blood group typing industry. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the blood group typing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Also, the high burden of chronic conditions on regional healthcare systems is another major driver for market growth.

Blood Group Typing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US). The market leadership of these players stems from their comprehensive product portfolios and expansive global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Blood Group Typing Industry:

Report Metric

Details

Market Revenue in 2023

$2.0 billion

Estimated Value by 2028

$3.0 billion

Revenue Rate

Poised to grow at a CAGR of 8.7%

Market Driver

The increasing prevalence of chronic diseases and the rising number of surgical procedures necessitate the need for blood donations

Market Opportunity

Growth opportunities in emerging economies

This report categorizes the blood group typing market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Consumables
    • Antisera Reagents
    • Anti-human Globulin Reagents
    • Red Blood Cell Reagents
    • Blood Bank Saline
  • Instruments
  • Services & Software

By Test Type

  • ABO Blood Tests & Rh Typing
  • Antibody Screening
  • HLA Typing
  • Cross-matching Tests
  • Antigen Typing

By Technique

  • Assay-based Techniques
  • PCR-based and Microarray Techniques
  • Massively Parallel Sequencing
  • Other Techniques

By End User

  • Hospitals
  • Blood Banks
  • Clinical Laboratories
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments of Blood Group Typing Industry:

  • In June 2023, Quotient Limited (Switzerland) launched its ALBA products in the Netherlands and Sweden in addition to the following geographies: Austria, France, Germany, Greece, Hungary, Italy, Luxembourg, the Netherlands, Poland, Romania, Slovakia, and Sweden.
  • In May 2023, Bio-Rad Laboratories, Inc. (US) launched the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System not only reduces instrument downtime and increases laboratory productivity but also provides the flexibility and freedom to use high-performing Bio-Rad Reagent Red Blood Cells (RBCs), as well as the lab’s own RBCs or third-party Reagent RBCs.
  • In March 2022, Quotient Limited (Switzerland) received the Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray. The expanded array of features of MosaiQ allows for the comprehensive characterization of blood donor samples (blood typing and disease screening) through a single test procedure.
  • In June 2023, Quotient Limited (Switzerland) and Transmedic Pte Ltd (Singapore) signed a distribution agreement, which will enable Transmedic to distribute Alba by Quotient and MosaiQ in five countries in Southeast Asia.
  • In March 2023, With the acquisition of Immucor, Inc. (US), Werfen (Spain) expanded its presence as a company of reference in the specialized diagnostics market and grew its portfolio of diagnostic solutions for hospitals and clinical laboratories.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 BLOOD GROUP TYPING MARKET
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 BLOOD GROUP TYPING INDUSTRY: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 GROWTH RATE ASSUMPTIONS 
    2.8 RISK ASSESSMENT 
           2.8.1 RISK ASSESSMENT: MARKET
    2.9 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 8 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 BLOOD GROUP TYPING MARKET OVERVIEW 
          FIGURE 13 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
    4.2 MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 
          FIGURE 14 CONSUMABLES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
    4.3 MARKET, BY TEST TYPE, 2023 VS. 2028 
          FIGURE 15 ABO BLOOD TESTS & RH TYPING SEGMENT TO DOMINATE MARKET IN 2028
    4.4 MARKET, BY TECHNIQUE, 2023 VS. 2028 
          FIGURE 16 ASSAY-BASED TECHNIQUES SEGMENT TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD
    4.5 MARKET, BY END USER, 2023 VS. 2028 
          FIGURE 17 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
    4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 BLOOD GROUP TYPING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations
                                FIGURE 20 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 2015–2030 (MILLION INDIVIDUALS)
                    5.2.1.2 Growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions
                    5.2.1.3 Increasing demand for blood group typing in prenatal testing
                    5.2.1.4 High usage of blood group typing in forensic sciences
                    5.2.1.5 Extensive R&D in blood typing
                    5.2.1.6 Stringent regulatory standards for blood transfusion
                                TABLE 1 LIST OF PRODUCTS CBER REGULATES
           5.2.2 RESTRAINTS
                    5.2.2.1 Emergence of blood alternatives
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in emerging economies
    5.3 PRICING ANALYSIS 
           5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
                    TABLE 2 INDICATIVE PRICING FOR BLOOD GROUP TYPING PRODUCTS
           5.3.2 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS, BY KEY PLAYER
                    TABLE 3 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS
    5.4 PATENT ANALYSIS 
          FIGURE 21 PATENT ANALYSIS FOR BLOOD GROUP TYPING REAGENTS (JANUARY 2013–DECEMBER 2022)
           5.4.1 LIST OF MAJOR PATENTS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS OF MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 23 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 24 MARKET: ECOSYSTEM ANALYSIS
           5.7.1 MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY LANDSCAPE 
          TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 7 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
          TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
                    TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                                TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.3 India
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
           5.9.5 MIDDLE EAST
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                     TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
                     TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES & EVENTS IN 2023–2024 
           TABLE 13 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.13 PESTLE ANALYSIS 
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 25 REVENUE SHIFT IN MARKET
    5.15 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS
                     TABLE 14 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS (%)
           5.15.2 BUYING CRITERIA
                     FIGURE 27 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
                     TABLE 15 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
           5.15.3 CASE STUDY ANALYSIS
 
6 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE (Page No. - 79)
    6.1 INTRODUCTION 
             TABLE 16 BLOOD GROUP TYPING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES 
             TABLE 17 KEY CONSUMABLES AVAILABLE IN MARKET
             TABLE 18 BLOOD GROUP TYPING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 19 BLOOD GROUP TYPING CONSUMABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
           6.2.1 ANTISERA REAGENTS
                    6.2.1.1 Increasing demand for cost-effective blood typing solutions to support uptake of antisera reagents
                                TABLE 20 ANTISERA REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 ANTI-HUMAN GLOBULIN REAGENTS
                    6.2.2.1 Increasing number of organ transplantations to drive uptake of AHG reagents
                                TABLE 21 ANTI-HUMAN GLOBULIN REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 RED BLOOD CELL REAGENTS
                    6.2.3.1 Higher compatibility of red blood cell reagents with variety of blood group typing techniques to support uptake
                                TABLE 22 RED BLOOD CELL REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 BLOOD BANK SALINE
                    6.2.4.1 Ability of blood bank saline to preserve integrity of RBCs to support market growth
                                TABLE 23 BLOOD BANK SALINE MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 GROWING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST DEMAND FOR BLOOD GROUP TYPING INSTRUMENTS
                    TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
                    TABLE 25 BLOOD GROUP TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.4 SERVICES & SOFTWARE 
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN MARKET SEGMENT
                    TABLE 26 BLOOD GROUP TYPING SERVICES & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 BLOOD GROUP TYPING MARKET, BY TEST TYPE (Page No. - 88)
    7.1 INTRODUCTION 
          TABLE 27 BLOOD GROUP TYPING INDUSTRY, BY TEST TYPE, 2021–2028 (USD MILLION)
    7.2 ABO BLOOD TESTS & RH TYPING 
           7.2.1 GROWING AWARENESS OF IMPORTANCE OF BLOOD DONATION TO DRIVE GROWTH
                    TABLE 28 MARKET FOR ABO BLOOD TESTS & RH TYPING, BY REGION, 2021–2028 (USD MILLION)
    7.3 ANTIBODY SCREENING 
           7.3.1 INCREASING INCIDENCE OF CANCER AND AUTOIMMUNE DISORDERS TO SUPPORT GROWTH
                    TABLE 29 MARKET FOR ANTIBODY SCREENING, BY REGION, 2021–2028 (USD MILLION)
    7.4 HLA TYPING 
           7.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO STIMULATE DEMAND FOR HLA TYPING
                    TABLE 30 MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION)
    7.5 CROSS-MATCHING TESTS 
           7.5.1 GROWING NEED FOR BLOOD TRANSFUSION TO PROPEL MARKET GROWTH
                    TABLE 31 MARKET FOR CROSS-MATCHING TESTS, BY REGION, 2021–2028 (USD MILLION)
    7.6 ANTIGEN TYPING 
           7.6.1 INCREASING CASES OF INCORRECT BLOOD TRANSFUSION TO FUEL GROWTH
                    TABLE 32 MARKET FOR ANTIGEN TYPING, BY REGION, 2021–2028 (USD MILLION)
 
8 BLOOD GROUP TYPING MARKET, BY TECHNIQUE (Page No. - 95)
    8.1 INTRODUCTION 
             TABLE 33 BLOOD GROUP TYPING INDUSTRY, BY TECHNIQUE, 2021–2028 (USD MILLION)
    8.2 ASSAY-BASED TECHNIQUES 
           8.2.1 AUTOMATION, SENSITIVITY, OBJECTIVITY, AND ADAPTABILITY OF ASSAY-BASED TECHNIQUES TO BOOST ADOPTION
                    TABLE 34 MARKET FOR ASSAY-BASED TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
    8.3 PCR-BASED AND MICROARRAY TECHNIQUES 
           8.3.1 HIGH ACCURACY OF PCR-BASED AND MICROARRAY TECHNIQUES TO SUPPORT GROWTH
                    TABLE 35 MARKET FOR PCR-BASED AND MICROARRAY TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
    8.4 MASSIVELY PARALLEL SEQUENCING 
           8.4.1 ABILITY TO DETECT LOW-FREQUENCY ALLELES TO DRIVE DEMAND FOR MPS TECHNIQUES
                    TABLE 36 MARKET FOR MASSIVELY PARALLEL SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER TECHNIQUES 
             TABLE 37 MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
 
9 BLOOD GROUP TYPING MARKET, BY END USER (Page No. - 100)
    9.1 INTRODUCTION 
          TABLE 38 BLOOD GROUP TYPING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 PRIMARY NOTES 
           9.2.1 KEY PRIMARY INSIGHTS
    9.3 HOSPITALS 
           9.3.1 INCREASING NUMBER OF HOSPITALS TO BOOST GROWTH
                    TABLE 39 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
    9.4 BLOOD BANKS 
           9.4.1 GROWING NUMBER OF BLOOD DONATIONS TO PROPEL MARKET GROWTH
                    TABLE 40 MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
    9.5 CLINICAL LABORATORIES 
           9.5.1 GROWING PREVALENCE OF BLOOD DISORDERS TO BOLSTER GROWTH
                    TABLE 41 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
    9.6 OTHER END USERS 
             TABLE 42 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
10 BLOOD GROUP TYPING MARKET, BY REGION (Page No. - 106)
     10.1 INTRODUCTION 
             TABLE 43 MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 28 NORTH AMERICA: BLOOD GROUP TYPING MARKET SNAPSHOT
             TABLE 44 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 45 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 46 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 47 NORTH AMERICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 48 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 NORTH AMERICA: RECESSION IMPACT
             10.2.2 US
                        10.2.2.1 Increasing prevalence of chronic conditions to drive market growth
                                      TABLE 49 ESTIMATED NUMBER OF SINGLE ORGAN TRANSPLANTS PERFORMED IN US
                                      TABLE 50 US: BLOOD GROUP TYPING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 51 US: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 52 US: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 53 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing incidence of blood cancer to boost market
                                      TABLE 54 CANADA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 55 CANADA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 56 CANADA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 57 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             TABLE 58 EUROPE: BLOOD GROUP TYPING INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 59 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 60 EUROPE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 61 EUROPE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 62 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 EUROPE: RECESSION IMPACT
             10.3.2 GERMANY
                        10.3.2.1 Increasing healthcare expenditure to drive market growth
                                      TABLE 63 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
                                      TABLE 64 GERMANY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 65 GERMANY: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 66 GERMANY: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 67 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Growing number of road accidents to propel market growth
                                      TABLE 68 UK: BLOOD GROUP TYPING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 69 UK: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 70 UK: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 71 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Rising R&D expenditure in France to drive market growth
                                      TABLE 72 FRANCE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 73 FRANCE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 74 FRANCE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 75 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Increasing number of blood donors to favor market growth
                                      TABLE 76 ITALY: BLOOD GROUP TYPING INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 77 ITALY: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 78 ITALY: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 79 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Consolidation of laboratories in Spain to support market growth
                                      TABLE 80 SPAIN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 81 SPAIN: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 82 SPAIN: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 83 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 84 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
                        TABLE 85 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 86 REST OF EUROPE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 87 REST OF EUROPE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 88 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 29 ASIA PACIFIC: BLOOD GROUP TYPING MARKET SNAPSHOT
             TABLE 89 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 90 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 91 ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 92 ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 93 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
             10.4.2 CHINA
                        10.4.2.1 Growing public access to modern healthcare to drive market growth
                                      TABLE 94 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                                      TABLE 95 CHINA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 96 CHINA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 97 CHINA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 98 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                      TABLE 99 JAPAN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 100 JAPAN: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 JAPAN: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 102 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Increasing private & public investments in healthcare system to drive market growth
                                      TABLE 103 INDIA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 104 INDIA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 105 INDIA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 106 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 107 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 108 REST OF ASIA PACIFIC: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 109 REST OF ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 110 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE TO SUPPORT MARKET GROWTH
                        TABLE 111 BRAZIL: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                        TABLE 112 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 113 LATIN AMERICA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 114 LATIN AMERICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 115 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 LATIN AMERICA: RECESSION IMPACT
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
                        TABLE 116 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 117 MIDDLE EAST & AFRICA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 118 MIDDLE EAST & AFRICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 119 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 152)
     11.1 OVERVIEW 
     11.2 STRATEGIES OF KEY PLAYERS 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLOBAL MARKET
                        TABLE 120 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD GROUP TYPING MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MARKET
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 31 BLOOD GROUP TYPING INDUSTRY SHARE, BY KEY PLAYER (2022)
             TABLE 121 MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022) 
             11.5.1 LIST OF EVALUATED VENDORS
             11.5.2 STARS
             11.5.3 EMERGING LEADERS
             11.5.4 PERVASIVE PLAYERS
             11.5.5 PARTICIPANTS
                        FIGURE 32 MARKET: COMPANY EVALUATION QUADRANT, 2022
     11.6 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 33 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
             11.6.5 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                        FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN MARKET
                        TABLE 122 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 123 COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 124 COMPANY REGIONAL FOOTPRINT
                        TABLE 125 BLOOD GROUP TYPING INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
     11.7 COMPETITIVE SCENARIO 
             11.7.1 PRODUCT LAUNCHES
                        TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–AUGUST 2023)
             11.7.2 DEALS
                        TABLE 127 KEY DEALS (JANUARY 2020–AUGUST 2023)

12 COMPANY PROFILES (Page No. - 165)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 KEY PLAYERS 
             12.1.1 BIO-RAD LABORATORIES, INC.
                        TABLE 128 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.2 QUIDELORTHO CORPORATION
                        TABLE 129 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 36 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.3 GRIFOLS, S.A.
                        TABLE 130 GRIFOLS, S.A.: BUSINESS OVERVIEW
                        FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
             12.1.4 THERMO FISHER SCIENTIFIC INC.
                        TABLE 131 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.5 IMMUCOR, INC.
                        TABLE 132 IMMUCOR, INC.: BUSINESS OVERVIEW
             12.1.6 QUOTIENT LIMITED
                        TABLE 133 QUOTIENT LIMITED: BUSINESS OVERVIEW
                        FIGURE 39 QUOTIENT LIMITED: COMPANY SNAPSHOT (2021)
             12.1.7 DANAHER
                        TABLE 134 DANAHER: BUSINESS OVERVIEW
                        FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022)
             12.1.8 MERCK KGAA
                        TABLE 135 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.9 NOVACYT
                        TABLE 136 NOVACYT: BUSINESS OVERVIEW
                        FIGURE 42 NOVACYT: COMPANY SNAPSHOT (2022)
             12.1.10 BAG HEALTH CARE GMBH
                        TABLE 137 BAG HEALTH CARE GMBH: BUSINESS OVERVIEW
             12.1.11 RAPID LABS LTD.
                        TABLE 138 RAPID LABS LTD.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 AGENA BIOSCIENCE, INC.
                        TABLE 139 AGENA BIOSCIENCE, INC.: COMPANY OVERVIEW
             12.2.2 BIOREX DIAGNOSTICS
                        TABLE 140 BIOREX DIAGNOSTICS: COMPANY OVERVIEW
             12.2.3 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH
                        TABLE 141 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW
             12.2.4 PRESTIGE DIAGNOSTICS
                        TABLE 142 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
             12.2.5 DIALAB GMBH
                        TABLE 143 DIALAB GMBH: COMPANY OVERVIEW
             12.2.6 LORNE LABORATORIES LIMITED
                        TABLE 144 LORNE LABORATORIES LIMITED: COMPANY OVERVIEW
             12.2.7 ATLAS MEDICAL GMBH
                        TABLE 145 ATLAS MEDICAL GMBH: COMPANY OVERVIEW
             12.2.8 TORAX BIOSCIENCES LIMITED
                        TABLE 146 TORAX BIOSCIENCES LIMITED: COMPANY OVERVIEW
             12.2.9 FORTRESS DIAGNOSTICS
                        TABLE 147 FORTRESS DIAGNOSTICS: COMPANY OVERVIEW
             12.2.10 AXO SCIENCE
                        TABLE 148 AXO SCIENCE: COMPANY OVERVIEW
             12.2.11 MAXWIN HEALTH CARE PVT. LTD.
                        TABLE 149 MAXWIN HEALTH CARE PVT. LTD.: COMPANY OVERVIEW
             12.2.12 ANAMOL LABORATORIES PVT. LTD.
                        TABLE 150 ANAMOL LABORATORIES PVT. LTD.: COMPANY OVERVIEW
             12.2.13 J. MITRA & CO. PVT. LTD.
                        TABLE 151 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
             12.2.14 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
                        TABLE 152 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 213)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

 

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the blood group typing market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Blood Group Typing Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Bio-rad Laboratories, Inc.

Senior Product Manager

Lorne Laboratories Limited

Quality Control Manager

Danaher

Marketing Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the blood group typing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the blood group typing market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Blood Group Typing Market Size: Bottom Up Approach

Blood Group Typing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Blood Group Typing Market Size: Top-Down Approach

Blood Group Typing Market Size, and Share

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Blood group typing is a classification system that depends on the presence of A or B antigens in red blood cells. The blood group is specifically determined by the type of antigens inherited from parents. These antigens are inherited traits that determine a person's blood group, which can be categorized into different blood types, such as A, B, AB, or O, along with the Rh factor (positive or negative). This information is vital for safe medical procedures involving blood or blood products and helps healthcare professionals ensure compatibility and minimize the risk of adverse reactions.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global blood group typing market by product & service, test type, technique, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, and opportunities)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall blood group typing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Available Customizations

MarketsandMarkets offers the following customizations for this market report.

Country Information

  • Additional country-level analysis of the blood group typing market

Company profiles

  • Additional five company profiles of players operating in the blood group typing market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the blood group typing market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5210
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Blood Group Typing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback